Treatment of Staphylococcus aureus Pneumonia in Adults Hospitalized with Nonsevere Community-Acquired Pneumonia
This protocol covers empiric management of adults admitted to hospital with nonsevere community-acquired pneumonia (CAP) due to Staphylococcus aureus — in patients who have not had prior respiratory isolation of MRSA or Pseudomonas aeruginosa and who have not been recently hospitalized with parenteral antibiotics in the preceding 90 days.
Clinical Scenario
The patient is a hospitalized adult presenting with nonsevere community-acquired pneumonia. The absence of specific risk factors — no prior respiratory isolation of MRSA or P. aeruginosa, and no recent hospitalization combined with parenteral antibiotic use within the last 90 days — defines this population and shapes the empiric antibiotic strategy.
Nonsevere CAP
No MRSA history
No P. aeruginosa history
No recent parenteral antibiotics
Empiric Treatment Approach
For this population, empiric therapy involves a beta-lactam-based combination regimen as the primary approach, with an alternative antibiotic class as monotherapy — the complete agent selection, sequencing, and switching criteria are in the full structured protocol.
Treatment Goals
The endpoint is clinical stability: resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation. Most patients achieve stability within 48 to 72 hours.
References
- In inpatient adults with nonsevere CAP without risk factors for MRSA or P. aeruginosa (see Recommendation 11), we recommend the following empiric treatment regimens (in no order of preference) (Table 4):
- Combination therapy with a beta-lactam (ampicillin + sulbactam 1.5–3 g every 6 h, cefotaxime 1–2 g every 8 h, ceftriaxone 1–2 g daily, or ceftaroline 600 mg every 12 h) and a macrolide (azithromycin 500 mg daily or clarithromycin 500 mg twice daily) (strong recommendation, high quality of evidence), or monotherapy with a respiratory fluoroquinolone (levofloxacin 750 mg daily, moxifloxacin 400 mg daily) (strong recommendation, high quality of evidence).
- We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).
- As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.
DOI: 10.1164/rccm.201908-1581ST
View source ↗